Transgenomic Inc. Launches Next Generation SURVEYOR(R) Mutation Detection Kits For Fluorescent Capillary Electrophoresis

Transgenomic, Inc.
(Nasdaq: TBIO) announced today that it is launching its next generation
SURVEYOR Mutation Detection Kits for universal primer fluorescent capillary
electrophoresis. The kits detect mismatch mutations in DNA that has been
PCR amplified using two fluorescent primers and digested with SURVEYOR
Nuclease. This then allows highly sensitive mutation detection on Applied
Biosystems DNA sequencing instruments. It will be a key tool for scientists
needing high-throughput analysis of genetic variation, even for those
variations present at very low levels such as somatic mutations linked to
cancer and its treatment.



Introduced by Transgenomic in 2004, SURVEYOR Nuclease is a proprietary
mismatch-specific endonuclease that efficiently detects any mismatches in
double-stranded DNA and cleaves at the site of DNA mutations. It identifies
all base substitutions, insertions and deletions and can detect multiple
mutations in a single fragment, in individual or even pooled PCR samples.
SURVEYOR Nuclease's effectiveness in disease specific mutation discovery
has been well documented in many peer-reviewed publications over the past
two years.



In announcing the product launch, Craig Tuttle, Transgenomic, Inc. CEO,
commented that, "We are excited to extend the SURVEYOR Mutation Detection
Kit product line and provide such an important research tool to detect
mutations that sequencing cannot find, or finds difficult to reveal.
SURVEYOR also saves researchers time and money with its increased
precision. SURVEYOR Endonuclease is an important expansion of
Transgenomic's mutation detection product portfolio which is exemplified by
our WAVE(R) System platforms and our emerging CLIA and GLP Clinical
Reference Laboratory and Genomic Analysis and Research Services."



To find out more about SURVEYOR Nuclease, go to transgenomic



About Transgenomic: A decade of discovery 1997 - 2007



Transgenomic is a global biotechnology company that provides unique
systems, products, discovery and laboratory testing services to the
academic and medical research, clinical and pharmaceutical markets for
automated high sensitivity genetic variation and mutation analysis in the
fields of pharmacogenomics and personalized medicine. This is accomplished
through their offerings of Wave(TM) DHPLC systems, reagents, consumables
and assay kits, automated cytogenetics systems and Transgenomic Discovery
and CLIA Lab Services. To date there have been over 1,200 Wave systems
installed in over 600 customer sites in over 35 countries and approximately
1,500 publications utilizing Transgenomic products or services.
Transgenomic Discovery and Lab Services utilize their technology and
expertise to provide a menu of mutation scanning tests for over 700
cancer-associated genes and more than 60 validated diagnostic tests to meet
the needs of pharmaceutical and biotech companies, research and clinical
laboratories, physicians and patients. For more information about the
innovative systems, products and services offered by Transgenomic, please
visit: transgenomic.
















Transgenomic Cautionary Statements



Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Forward-looking statements
include, but are not limited to, those with respect to management's current
views and estimates of future economic circumstances, industry conditions,
company performance and financial results, including the ability of the
Company to grow its involvement in the diagnostic products and services
markets. The known risks, uncertainties and other factors affecting these
forward-looking statements are described from time to time in
Transgenomic's reports to the Securities and Exchange Commission. Any
change in such factors, risks and uncertainties may cause the actual
results, events and performance to differ materially from those referred to
in such statements. Accordingly, the company claims the protection of the
safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 with respect to all statements
contained in this press release. All information in this press release is
as of the date of the release and Transgenomic does not undertake any duty
to update this information, including any forward-looking statements,
unless required by law.


Transgenomic, Inc.

transgenomic